Raloxifene Relaxes Rat Cerebral Arteries In Vitro and Inhibits L-Type Voltage-Sensitive Ca 2+ Channels
- 1 July 2004
- journal article
- research article
- Published by Wolters Kluwer Health in Stroke
- Vol. 35 (7) , 1709-1714
- https://doi.org/10.1161/01.str.0000131479.08005.ca
Abstract
Background and Purpose— Because of their mixed estrogen-agonist and estrogen-antagonist properties, selective estrogen receptor modulators (SERMs) are considered promising substitutes for hormone replacement therapy. Raloxifene and other SERMs confer estrogen-like cardiovascular protective effects but lack the carcinogenic activity of exogenous estrogen. However, little is known about the cerebrovascular action of raloxifene. Therefore, we studied the effects of raloxifene on the mechanisms regulating rat cerebral artery tone. Methods and Results— Ring segments of the isolated rat posterior communicating cerebral arteries were mounted in a microvessel myograph for measurement of isometric tension. Whole-cell L-type voltage-sensitive Ca 2+ currents were recorded using the perforated patch-clamp technique. Raloxifene (0.1 to 10 μmol/L) reduced the contractile responses to U46619, phenylephrine, and endothelin-1 in normal Krebs solution or to CaCl 2 in Ca 2+ -free, high K + -containing solution. Raloxifene-induced relaxation was identical in endothelium-intact and endothelium-denuded rings. ICI 182780 had no effect on raloxifene-induced relaxation. Raloxifene reduced L-type Ca 2+ currents with a p D 2 of 5.98±0.06, close to that (6.44±0.09) for raloxifene-induced relaxation of 60 mmol/L K + -contracted rings. Conclusions— This study demonstrates that raloxifene acutely relaxes rat cerebral arteries largely via an endothelium-independent mechanism, involving inhibition of Ca 2+ influx through L-type Ca 2+ channels.Keywords
This publication has 17 references indexed in Scilit:
- Estrogen and raloxifene induce apoptosis by activating p38 mitogen-activated protein kinase cascade in synthetic vascular smooth muscle cellsJournal of Endocrinology, 2003
- Raloxifene Concurrently Stimulates Osteoprotegerin and Inhibits Interleukin-6 Production by Human Trabecular OsteoblastsJournal of Clinical Endocrinology & Metabolism, 2003
- Selective Estrogen-Receptor Modulators — Mechanisms of Action and Application to Clinical PracticeNew England Journal of Medicine, 2003
- Pharmacokinetics of Selective Estrogen Receptor ModulatorsClinical Pharmacokinetics, 2003
- Risks and Benefits of Estrogen Plus Progestin in Healthy Postmenopausal Women: Principal Results From the Women's Health Initiative Randomized Controlled TrialJAMA, 2002
- Cilnidipine is a novel slow-acting blocker of vascular L-type calcium channels that does not target protein kinase CJournal Of Hypertension, 2002
- Menopause and ischaemic stroke: basic, clinical and epidemiological considerations. The role of hormone replacement.Human Reproduction Update, 2002
- Raloxifene reduces impedance to flow within the uterine artery in early postmenopausal women: A 2-year randomized, placebo-controlled, comparative studyAmerican Journal of Obstetrics and Gynecology, 2001
- Randomized Trial of Estrogen Plus Progestin for Secondary Prevention of Coronary Heart Disease in Postmenopausal WomenJAMA, 1998
- Effects of Raloxifene on Bone Mineral Density, Serum Cholesterol Concentrations, and Uterine Endometrium in Postmenopausal WomenNew England Journal of Medicine, 1997